The Aspen Group (TAG) posted near double-digit revenue growth across its 1,400-location portfolio in 2025, reinforcing its position as the largest privately held dental services organization in the United States. The company served 9 million patients across its brands — Aspen Dental, ClearChoice, and WellNow — with Aspen Dental alone accounting for 5.2 million visits and 21 new office openings during the year. ClearChoice, the implant-focused brand, treated 27,500 full-arch patients and expanded into three new markets. On the technology front, TAG reported that AI-enabled diagnostic tools drove a 12% lift in care acceptance in pilot markets — a metric that translates directly to revenue per patient. The organization also delivered 50,000 3D-printed dental prostheses and donated $15 million in charitable care.

TAG's results illustrate the playbook that has made large DSOs the dominant growth engine in dentistry. The company combines national scale (brand recognition, centralized procurement, shared services) with local clinical autonomy, a model that has attracted over $10 billion in aggregate PE investment into the DSO sector since 2020. The 12% care acceptance lift from AI diagnostics is particularly significant — it suggests that technology-driven clinical decision support is moving beyond pilot stage and into measurable revenue impact. For a network of TAG's size, even a few percentage points of acceptance improvement across 9 million patient visits represents hundreds of millions in incremental production.

The competitive implications are sharpening. TAG's continued expansion — 21 new de novo offices in a single year — pressures independent practices and smaller DSOs in overlapping markets. ClearChoice's three-market expansion signals that the high-value implant segment, which commands $20,000–$50,000 per case, remains a priority growth vector. The 50,000 3D-printed prostheses point to TAG's investment in vertically integrated lab capacity, which reduces per-unit costs and turnaround times while creating a barrier to entry for competitors lacking in-house manufacturing. For mid-market DSOs evaluating their positioning, TAG's results underscore the scale advantages that are increasingly difficult to replicate without significant capital investment.

Watch for TAG's AI diagnostic rollout beyond pilot markets — if the 12% care acceptance lift holds at scale, expect other large DSOs to accelerate their own AI investments. Monitor whether TAG pursues additional acquisitions in 2026 or continues prioritizing de novo growth, which carries lower integration risk but slower market penetration. Track ClearChoice's implant volume trajectory as competitors like Affordable Care and Clear Dental enter the full-arch space. And keep an eye on TAG's eventual exit timeline — the company has been PE-backed since its 2018 restructuring, and its 2025 performance could set the stage for an IPO or secondary sale in the current cycle.